CD274 and cancer: Given small sample sizes and inconsistent results of predictive markers studies across different cancer types, Lu et al. [134] performed a meta-analysis to examine a range of biomarkers such as IHC expression of PD-L1 (PD-L1 IHC), TMB, GEP, and multiplex immunohistochemistry/immunofluorescence (mIHC/IF) assays, alone or combined, and determine their relationships with objective response to anti-PD-(L)1therapies.